Clinical trial
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
NCT00376064 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00376064 |
|---|---|
| Title | Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly |
| Official title | A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acromegaly |
| Intervention type | Drug |
| Interventions | Octreotide acetate and cabergoline/Octrotide and Somavert |
| Enrollment | 20 |
| Start date | Mar 1, 2006 |
| Primary completion | Jan 1, 2010 |
| First posted | Sep 14, 2006 |
| Last update posted | Mar 6, 2017 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: